TCR2 Therapeutics Inc (NASDAQ:TCRR)

1.27
Delayed Data
As of Nov 28
 -0.02 / -1.55%
Today’s Change
1.23
Today|||52-Week Range
5.51
-72.75%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$49.9M

Company Description

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.

Contact Information

TCR2 Therapeutics, Inc.
100 Binney Street
Cambridge Massachusetts 02142
P:(617) 949-5200
Investor Relations:
(167) 949-5667

Employees

Shareholders

Individual stakeholders9.51%
Other institutional36.66%
Mutual fund holders10.91%

Top Executives

Garry E. MenzelPresident, Chief Executive Officer & Director
Eric M. SullivanChief Financial Officer
Alfonso Quintás-CardamaChief Medical Officer
Praveen MalhotraVice President-Information Technology
Peter OlagunjuChief Technical Officer